Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia
A recent study indicates that tirzepatide may reduce incident dementia more than semaglutide or SGLT2 inhibitors in adults with type 2 diabetes.
The No-Hunger Games- How GLP-1 Medication Adoption Is Changing Consumer Food Dem
GLP-1 medications lead to significant reductions in grocery spending, particularly in calorie-dense foods. This impact persists during medication use but reverses upon discontinuation.
Beyond weight loss- tirzepatide as a dual GIP:GLP-1 receptor agonist for obstruc
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been FDA-approved for treating moderate-to-severe OSA in obese adults. It significantly reduces AHI and improves sleep quality.
Cancer Incidence Among Users of Glucagon‑Like Peptide‑1 Receptor Agonists
A study involving over 106,000 patients found that GLP-1RA use was associated with a significantly lower risk of liver and pancreatic cancer compared to insulin.
Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuing GLP-1s
Stopping GLP-1 receptor agonists leads to substantial weight regain and reverses cardiometabolic benefits within a year. Early discontinuers face elevated cardiovascular risks.
Converging neurotrophic-immune signaling in autism spectrum disorder
This review examines the role of four interconnected signaling pathways in autism spectrum disorder. Among them, IGF-1 shows clinical trial support, while others remain preclinical or mechanistic.
Dietary Fiber and Glucagon-Like Peptide-1 Receptor Agonists in Obesity Managemen
GLP-1 receptor agonists and dietary fibers converge on the gut-brain axis, offering complementary benefits. This review examines their synergies and potential interactions in weight loss and maintenance.
Dysesthesia associated with GLP-1 agonist therapies- data-mining analysis
A study reveals that GLP-1 agonists like semaglutide are linked to significant signals for hyperesthesia, dysesthesia, and burning sensation. These reactions are dose-dependent and can recur upon rechallenge.
Efficacy and safety of GLP-1 receptor agonists in Parkinson’s disease- a systematic review
A recent study examines the use of GLP-1RAs in Parkinson's disease, finding no significant motor benefits but some improvement in quality of life.
Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Wegovy and Monjaro
GLP-1 receptor agonists offer significant health benefits but raise ethical concerns about long-term safety, access equity, and societal impacts.